MM_Hub: CONGRESS|#EHA2021| Philip Moreau later discussed development of CART cell therapy, benefits & limitations for MM pts including various studies such as KarMMa, JNJ4528 CAR, CARTITUDE 1 & MAMMOTH #mmsm #myeloma CHU Hotel-Dieu, France.

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA2021| Philip Moreau later discussed development of CART cell therapy, benefits & limitations for MM pts including various studies such as KarMMa, JNJ4528 CAR, CARTITUDE 1 & MAMMOTH #mmsm #myeloma CHU Hotel-Dieu, France. pic.twitter.com/lPmCqk61us—...

MM_Hub: CONGRESS|#EHA2021|Philip Moreau highlighted the use of new treatment approaches in clinical practice in MM. Treatment preferences for pts, refractory to lenlidomide after 1st, 2nd or 3rd relapse were also discussed #mmsm, #myeloma, CHU Hotel-Dieu, France

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA2021|Philip Moreau highlighted the use of new treatment approaches in clinical practice in MM. Treatment preferences for pts, refractory to lenlidomide after 1st, 2nd or 3rd relapse were also discussed #mmsm, #myeloma, CHU Hotel-Dieu, France...

MM_Hub: CONGRESS|#EHA2021|Neils van de Donk reported results from 1st in-human, Phase-1 study of teclistamb in R/R-MM pts. At the RP2D of weekly 1500 μg/kg SC, it was well-tolerated with durable deepening responses #mmsm, #myeloma, Amsterdam University Medical Center, Netherlands

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA2021|Neils van de Donk reported results from 1st in-human, Phase-1 study of teclistamb in R/R-MM pts. At the RP2D of weekly 1500 μg/kg SC, it was well-tolerated with durable deepening responses #mmsm, #myeloma, Amsterdam University Medical Center,...

managingmyeloma: 🆕#CME #CPE 🔛MDS: Novel Promising Strategies ➡️ “A very exciting group of molecules called anti‐CD 4⃣7⃣antibodies which cover up the so‐called “don’t eat me” 🚦🔛the surface of the MDS cell & allow the macrophages to eat or kill the noxious cell.” #Meded

by | Jun 11, 2021 | Twitter

🆕#CME #CPE 🔛MDS: Novel Promising Strategies ➡️https://t.co/Z8PpsxM2U7″A very exciting group of molecules called anti‐CD 4⃣7⃣antibodies which cover up the so‐called “don’t eat me” 🚦🔛the surface of the MDS cell & allow the macrophages to eat...

MM_Hub: CONGRESS|#EHA2021| Wang Di, presented data on BCMA-targeting CAR construct (CT103A), safety & efficacy. CT103A is safe, highly productive with long persistent in RRMM patients #mmsm #myeloma, Huazhong University of Science & Technology, Wuhan

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA2021| Wang Di, presented data on BCMA-targeting CAR construct (CT103A), safety & efficacy. CT103A is safe, highly productive with long persistent in RRMM patients #mmsm #myeloma, Huazhong University of Science & Technology, Wuhan...